Design of a Phase 3, Global, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn
American Journal of Perinatology · 2025-05 · 42 (07) · 842-853
DOI: 10.1055/a-2404-8089 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Perinatology, online erschienen am 17.09.2024. Verfasst von Yosuke Komatsu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Janssen Pharmaceutical Companies of Johnson and Johnson, Cambridge, Massachusetts. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Erythroblastosis, Fetal. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Janssen Research & Development, LLC, Janssen Global Services, LLC.
Abstract (Originalsprache)
Nipocalimab is a neonatal fragment crystallizable (Fc) receptor (FcRn)—blocking monoclonal antibody that inhibits placental immunoglobulin G (IgG) transfer and lowers circulating maternal IgG levels. In an open-label, single-arm, phase 2 study, nipocalimab demonstrated evidence of safety and efficacy that support further investigation in a pivotal phase 3 trial of recurrent hemolytic disease of the fetus and newborn (HDFN). The phase 3 AZALEA study aims to evaluate the efficacy and safety of nipocalimab in a larger population at risk for severe HDFN, defined as HDFN associated with poor fetal outcomes or neonatal death. AZALEA is a multicenter, randomized, placebo-controlled, double-blind, phase 3 study enrolling alloimmunized pregnant individuals (N ≈ 120) at risk for severe HDFN based on obstetric history. Participants are randomized 2:1 to receive intravenous 45 mg/kg nipocalimab or placebo weekly from 13–16 to 35 weeks gestational age (GA). During the double-blind treatment period, participants receive standard-of-care weekly monitoring for fetal anemia until planned delivery at 37 to 38 weeks of GA. Postnatal follow-up periods are 24 weeks for maternal participants and 104 weeks for neonates/infants. The primary endpoint is the proportion of pregnancies that do not result in intrauterine transfusion (IUT), hydrops fetalis, or fetal loss/neonatal death from all causes. Key secondary endpoints include the severity of HDFN as measured by a composite HDFN severity index, the earliest time to occurrence of IUT or hydrops fetalis, the modified neonatal mortality and morbidity index in liveborn neonates, and the number of IUTs received. Other endpoints are safety, patient- and caregiver-reported outcomes, pharmacokinetics, pharmacodynamics (e.g., IgG, FcRn receptor occupancy), and immunogenicity of nipocalimab. AZALEA, the first placebo-controlled, randomized, multicenter, prospective trial in severe HDFN, is designed to evaluate the safety and efficacy of nipocalimab, a potential preventive and noninvasive intervention, in at-risk HDFN pregnancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Janssen Pharmaceutical Companies of Johnson and Johnson, Cambridge, Massachusetts.
- Division of Fetal Therapy, Department of Obstetrics, Leiden University Medical Center, Leiden, The Netherlands.
- Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
- Division of Neonatology, Department of Pediatrics, Leiden University Medical Center, Leiden, The Netherlands.
- Dell Medical School, The University of Texas at Austin, Austin, Texas.
- Comprehensive Fetal Care Center at Dell Children's Medical Center, Austin, Texas.
ORCID-Profile: Kenneth J Moise
Förderung
- Janssen Research & Development, LLC
- Janssen Global Services, LLC
Zitieren
APA
Komatsu, Y., Verweij, E. J. T. J., Tiblad, E., Lopriore, E., Oepkes, D., Agarwal, P., Lam, E., Leu, J. H., Ling, L. E., Nelson, R. M., Olusajo, V., Saeed-Khawaja, S., Tjoa, M. L., Zhou, J., Amin, U., Sirah, W., & Moise, K. J. (2025). Design of a Phase 3, Global, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn. American Journal of Perinatology, 42(07), 842-853. https://doi.org/10.1055/a-2404-8089
Vancouver
Komatsu Y, Verweij EJTJ, Tiblad E, Lopriore E, Oepkes D, Agarwal P, et al. Design of a Phase 3, Global, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn. American Journal of Perinatology. 2025;42(07):842-853. doi:10.1055/a-2404-8089
BibTeX
@article{Komatsu2025,
author = {Komatsu, Yosuke and Verweij, E J T Joanne and Tiblad, Eleonor and Lopriore, Enrico and Oepkes, Dick and Agarwal, Prasheen and Lam, Edwin and Leu, Jocelyn H and Ling, Leona E and Nelson, Robert M and Olusajo, Victor and Saeed-Khawaja, Shumyla and Tjoa, May Lee and Zhou, Jie and Amin, Umair and Sirah, Waheeda and Moise, Kenneth J},
title = {Design of a Phase 3, Global, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn},
journal = {American Journal of Perinatology},
year = {2025},
volume = {42},
number = {07},
pages = {842--853},
doi = {10.1055/a-2404-8089}
}
EUVIMED